Lab Information
Andréanne Lupien (PhD)
Junior ScientistCentre for Translational Biology
Department of Microbiology & Immunology (McGill)
Research Profile
Keywords
Tuberculosis • non-tuberculous mycobacteria • drug development, tuberculosis preventive treatment • drug resistance • molecular biologyResearch Interests
My research mainly focuses on evaluating and developing new treatments against tuberculosis (TB) and non-tuberculous mycobacterial infections. Specifically, I investigate how mycobacteria resist current treatments and aim to develop new therapies. My work includes optimizing new tuberculosis preventive treatments (TPT) for latent TB infections and characterizing new compounds and regimens against Mycobacterium tuberculosis and non-tuberculous mycobacteria from the initial discovery (hit identification and hit-to-lead optimization) to pre-clinical studies.Team Members
| Name | Position |
|---|
Latest Publications
- Duffy, S. C., Lupien, A., Elhaji, Y., Farag, M., Marcus, V. & Behr, M. A. (2023). Establishment of persistent enteric mycobacterial infection following streptomycin pre-treatment. Gut pathogens, vol. 15, p. 46.
- Sullivan, J. R., Yao, J., Courtine, C., Lupien, A., Herrmann, J., Müller, R. & Behr, M. A. (2022). Natural Products Lysobactin and Sorangicin A Show In Vitro Activity against Mycobacterium abscessus Complex. Microbiology spectrum, vol. 10, p. e0267222.
- Kaufmann, E., Khan, N., Tran, K. A., Ulndreaj, A., Pernet, E., Fontes, G., Lupien, A., Desmeules, P., McIntosh, F., Abow, A., Moorlag, S. J. C. F. M., Debisarun, P., Mossman, K., Banerjee, A., Karo-Atar, D., Sadeghi, M., Mubareka, S., Vinh, D. C., King, I. L., Robbins, C. S., Behr, M. A., Netea, M. G., Joubert, P. & Divangahi, M. (2022). BCG vaccination provides protection against IAV but not SARS-CoV-2. Cell reports, vol. 38, p. 110502.
- Sullivan, J. R., Lupien, A., Kalthoff, E., Hamela, C., Taylor, L., Munro, K. A., Schmeing, T. M., Kremer, L. & Behr, M. A. (2021). Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline. PLoS pathogens, vol. 17, p. e1009965.
- Camargo, C., Lupien, A., McIntosh, F., Menzies, D., Behr, M. A. & Sagan, S. M. (2022). Effectiveness of germicidal ultraviolet light to inactivate coronaviruses on personal protective equipment to reduce nosocomial transmission. Infection control and hospital epidemiology, vol. 43, p. 886-891.
- Duncan, D., Lupien, A., Behr, M. A. & Auclair, K. (2021). Effect of pH on the antimicrobial activity of the macrophage metabolite itaconate. Microbiology (Reading, England), vol. 167.
- Lupien, A., Foo, C.-S., Savina, S., Vocat, A., Piton, J., Monakhova, N., Benjak, A., Lamprecht, D. A., Steyn, A. J. C., Pethe, K., Makarov, V. A. & Cole, S. T. (2020). New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis. PLoS pathogens, vol. 16, p. e1008270.
- Foo, C. S., Lupien, A., Kienle, M., Vocat, A., Benjak, A., Sommer, R., Lamprecht, D. A., Steyn, A. J. C., Pethe, K., Piton, J., Altmann, K.-H. & Cole, S. T. (2018). Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis. mBio, vol. 9.
- Lupien, A., Vocat, A., Foo, C.-S., Blattes, E., Gillon, J.-Y., Makarov, V. & Cole, S. T. (2018). Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169). Antimicrobial agents and chemotherapy, vol. 62.
- Piton, J., Vocat, A., Lupien, A., Foo, C. S., Riabova, O., Makarov, V. & Cole, S. T. (2018). Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, vol. 62.
See also
